Blumenkron D, Rivera C, Cuevas C

Language: Spanish
References: 19
Page: 25-31
PDF size: 247.59 Kb.

ABSTRACT

Background: Migraine is a chronic disease characterized by recurrent attacks of severe headaches. It has neurological (aura) and systemic manifestations that can cause substantial disability.
Objective: To assess the effectiveness of the treatment with botulinum toxin type A in patients with migraine.
Patients and method: We included 30 patients that met the international criteria for the diagnosis of migraine. They were divided into two groups: group 1 received placebo, and group 2 received botulinum toxin.
Results: In the placebo group we observed diminution in the symptoms of migraine in two patients that had severe disability; one patient had mild disability. In the botulinum toxin group there was diminution of it in nine patients that had severe disability; only one patient had mild disability. The p value was › .9.
Conclusions: Botulinum toxin type A can be considered a preventive treatment in patients with migraine.

REFERENCES

1. Stane P, Osterhaus J, Celentano D. Migraine, patterns of healthcare use. Neurology 1994;44:S47-S55.

2. Hu X, Markson L, Lipton R, et al. Burden of migraine in the United States disability and economic costs. Arch Intern Med 1999;159:813-8.

3. Moskowitz M. The neurobiology of vascular head pain. Ann Neurol 1985;16:157-68.

4. Goadsby P, Shelley S. High-frequency stimulation of the facial nerve results in local cortical release of vasoactive intestinal polypeptide in the anesthetised cat. Neurosci Lett 1990;112:282-9.

5. Ramadan N, Silberstein S, Freitab T, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. 2000. www.aan.com/professionale/practice/guidelines.cfm

6. Brin M, Swope D, O’Brien C. Botox for migraine: double blind, placebo-controlled, region-specific evaluation (abstract). Cephalalgia 2000;20:421.

7. Mauskop A, Basedo R. Botulinum toxin A is an effective prophylactic therapy for migraine (abstract). Cephalalgia 2000;20:422.

8. Erbguth F, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the “sausage poison”. Neurology 1999;53:1850-3.

9. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7.

10. Dodick D. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from the bench to bedside. Headache 2003;42(Suppl 1):S25-S33.

11. Brin M. Treatment of dystonia. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders: New York: Williams & Wilkins, 1998;pp:553-78.

12. Black J, Dolly J. Selective location of acceptors for botulinum toxin A in the central and peripheral nervous system. Neuroscience 1987;23:767-79.

13. Suzuki N, Hardebo J. Neuropeptide Y coexists with vasoactive intestinal polypeptide and acetylcholine in parasympathetic cerebrovascular nerves originating in the sphenopalatine, otic and internal carotid ganglia of the rat. Neuroscience 1990;36:507-19.

14. El Hasnaoui A, Vray M, Richard A, et al. Assessing the severity of migraine: development of the MI GSE V scale. Headache 2003;43:628-35.

15. Wagner T, Patrick D, Galer B, et al. A new instrument to assess the long-term quality of life effects from migraine; development and psychometric testing of the MS QOL . Headache 1996;36:484-92.

16. Stewart W, Lipton R, Whyte J. An international study to assess reliability of the Migraine Disability Assessment (MI DAS ) score. Neurology 1999;53:988-9.

17. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in headache. Presented at 6th Headache Congress of the European Headache Federation. June 26-30, 2002; Istanbul Turkey. Abstract 81.

18. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin A as a migraine preventive treatment. For the Botox Migraine Clinical Research Group. Headache 2000;40:445-50.

19. Headache classification committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;(Suppl 7):1-96.